A
Adnan Tufail
Researcher at Moorfields Eye Hospital
Publications - 274
Citations - 12126
Adnan Tufail is an academic researcher from Moorfields Eye Hospital. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 52, co-authored 256 publications receiving 9323 citations. Previous affiliations of Adnan Tufail include UCL Institute of Ophthalmology & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Diagnostic accuracy of diabetic retinopathy grading by an artificial intelligence-enabled algorithm compared with a human standard for wide-field true-colour confocal scanning and standard digital retinal images.
Abraham Olvera-Barrios,Abraham Olvera-Barrios,Tjebo F. C. Heeren,Tjebo F. C. Heeren,Konstantinos Balaskas,Ryan Chambers,Louis Bolter,Catherine A Egan,Catherine A Egan,Adnan Tufail,Adnan Tufail,John Anderson +11 more
TL;DR: EyeArt identified diabetic retinopathy in EIDON images with similar sensitivity to standard images in a large-scale screening programme, exceeding the sensitivity threshold recommended for a screening test.
Journal ArticleDOI
Long-term outcomes following full macular translocation surgery in neovascular age-related macular degeneration.
TL;DR: With close post-operative monitoring and early treatment of delayed complications, 25% of this cohort maintained a three-line gain in acuity at 3 years after macular translocation.
Journal ArticleDOI
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
TL;DR: The real-world outcomes of ranibizumab therapy in this initial cohort of patients with nAMD are comparable with those reported in the pivotal, randomized, controlled trials using fewer injections and a prn strategy of retreatment to achieve the gain in visual acuity.
Journal ArticleDOI
Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom
Miranda Buckle,Aaron Y Lee,Quresh Mohamed,Emily Fletcher,Ahmed Sallam,Rachel Healy,Irene M Stratton,Adnan Tufail,R L Johnston +8 more
TL;DR: The incidence and prevalence of eligibility for certification of blindness or sight impairment in patients treated with ranibizumab for nAMD is low in Gloucestershire, with only 3.6% of the incident population progressing to blindness in 2010.
Journal ArticleDOI
The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
TL;DR: In Initiating treatment immediately with ranibizumab PRN regimen is a cost-effective strategy compared with current guidance of initiating treatment at a level of 6/12 or worse vision.